- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01175928
Pneumatic Medicine: A Transformative Treatment for Diabetic Peripheral Neuropathy
Phase 2 Study of the NormaTec PCD in the Treatment of Diabetic Peripheral Neuropathy
The purpose of this study is to evaluate the efficacy of the NormaTec PCD, a non-invasive pneumatic compression device with the patented peristaltic pulse pneumatic waveform, in the treatment of Diabetic Peripheral Neuropathy (DPN).
The study will compare treatment with a NormaTec PCD and a sham device to assess whether the NormaTec PCD improves the signs and symptoms of DPN.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes frequently leads to decreased sensation in the legs caused by diabetic peripheral neuropathy (DPN). DPN is an important risk factor for the development of foot ulceration, one of the most common causes for hospital admissions and lower-limb amputations among diabetic patients. However, to date there are no medications currently approved by the Food and Drug Administration to treat DPN.
The goal of this research project is to assess the effectiveness of a non-invasive, patented peristaltic pulse pneumatic compression device (the NormaTec PCD) in a home treatment program to improve the symptoms of DPN (e.g. numbness, pain, and tingling in the legs) and the underlying functioning of the nerves in the legs (as determined by sensory perception assessments and Nerve Conduction Studies testing).
In this prospective, randomized, double-blind study, subjects will be randomly placed in one of two groups: a control group using a sham NormaTec PCD ("placebo"); and an experimental group using a NormaTec PCD.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Newton Center, Massachusetts, United States, 02459
- NormaTec
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient diagnosed with type 1 or type 2 diabetes
- Patient diagnosed with distal symmetric polyneuropathy (DPN) attributable to diabetes
- A1C ≤ 11%
- Abnormal peroneal motor nerve conduction study where CMAP amplitude is less than 4 mV bilaterally.
Exclusion Criteria:
- Refuses consent
- Unlikely to be compliant with the research protocol as judged by the clinical investigator
- Neuropathy documented to be caused by something other than diabetes
- Medication for neuropathic pain initiated within the previous 3 months (to avoid confounding the results of the study)
- Medication for glucose control changed within the previous 3 months (to avoid confounding the results of the study)
- Documented DVT within the previous 3 months (since an acute DVT is a contraindication for Pneumatic Medicine treatment)
- Significant hepatic disease as judged by the clinical investigator (that might cause neuropathy unrelated to diabetes)
- Documented cancer treatment within the past 5 years (that might cause neuropathy unrelated to diabetes)
- History of exposure to neurotoxins or heavy metals (that might cause neuropathy unrelated to diabetes)
- Documented alcohol or drug abuse (that might cause neuropathy unrelated to diabetes)
- Documented major psychiatric disorder (that could contribute to non-adherence to the protocol)
- Presence of a major lower extremity amputation (since unable to perform bilateral distal sensory perception testing of the feet and NCS on the peroneal motor nerve)
- Significant peripheral arterial disease defined as an ankle-brachial index ("ABI") < 0.6 (to avoid critical limb ischemia and thus the high likelihood of the patient requiring a major amputation in the near future with drop out from the study)
- Severe lower extremity edema as judged by the clinical investigator (in order to not confound the results)
- End stage DPN where the peroneal motor nerve conduction results of both legs show an Amplitude = 0 mV
- Currently participating in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Peristaltic Pulse PCD
Peristaltic Pulse Pneumatic Compression Device (NormaTec PCD)
|
Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
Other Names:
|
Sham Comparator: Sham Device
Sham Pneumatic Compression Device (looks and sounds like real device, but applies no compression)
|
Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nerve Conduction Studies
Time Frame: 3 months
|
Nerve conduction studies of the peroneal motor nerve performed bilaterally (amplitude, velocity, distal latency).
|
3 months
|
Nerve Conduction Studies
Time Frame: 1 month
|
Nerve conduction studies of the peroneal motor nerve performed bilaterally (amplitude, velocity, distal latency).
|
1 month
|
Nerve Conduction Studies
Time Frame: 2 months
|
Nerve conduction studies of the peroneal motor nerve performed bilaterally (amplitude, velocity, distal latency).
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensory perception measurements
Time Frame: baseline; 1 month; 2 months; 3 months
|
Non-invasive sensory perception will be assessed with a 10-g monofilament (pressure); a 128 Hz tuning fork and a Neurothesiometer (vibration); a toothpick (sharp sensation); a cotton ball (soft sensation); an iced tuning fork (cold sensation); and calculation of the Neuropathy Disability Score.
|
baseline; 1 month; 2 months; 3 months
|
Quality of life questionnaires
Time Frame: baseline; 1 month; 2 months; 3 months
|
The following questionnaires will be self-administered: Norfolk Quality-of-Life Questionnaire for Diabetic Neuropathy (QOL-DN); Neuropathy Total Symptom Score-6 (NTSS-6); Problem Areas in Diabetes (PAID)
|
baseline; 1 month; 2 months; 3 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Nicholas Spirito, MD, Saints Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NormaTec_90513134-01
- 1R43DK088634-01 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Polyneuropathy
-
Eva PharmaMARC-CRORecruiting
-
Imperial College LondonActegy Ltd.Not yet recruitingDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Diabetic Polyneuropathy | Diabetic ComplicationUnited Kingdom
-
Ilko Ilac San. ve Tic. A.S.CompletedPeripheral (Sensorimotor) Diabetic Polyneuropathy
-
Mundipharma Research GmbH & Co KGCompletedModerate to Severe Pain Due to Diabetic PolyneuropathyGermany
-
Maastricht University Medical CenterZonMw: The Netherlands Organisation for Health Research and DevelopmentCompletedDiabetic Patients With PolyneuropathyNetherlands
-
NycomedCompletedSymptomatic Diabetic Peripheral PolyneuropathyDenmark
-
Timothy J. Best Medicine Professional CorporationThe Physicians' Services Incorporated FoundationCompleted
-
MEDA Pharma GmbH & Co. KGCompletedDiabetic PolyneuropathyIsrael, Russian Federation
-
Eisai Inc.CompletedMild to Moderate Diabetic Sensorimotor PolyneuropathyUnited States
-
Eastern Virginia Medical SchoolNational Institutes of Health (NIH)CompletedDiabetic; Neuropathic, Polyneuropathy (Manifestation)United States
Clinical Trials on NormaTec PCD (Peristaltic Pulse PCD)
-
White River Junction Veterans Affairs Medical CenterNormaTec Industries LPUnknownIntermittent ClaudicationUnited States
-
Boston Children's HospitalNormaTec Industries LPWithdrawnLymphedemaUnited States
-
Temple UniversityNutrisystem, Inc.CompletedType 2 DiabetesUnited States
-
Medical University of WarsawCompleted
-
University of Texas Southwestern Medical CenterCompletedIntubation of Pediatric Dental Surgery PatientsUnited States
-
The Cleveland ClinicTerminatedIntubationUnited States
-
Baylor College of MedicineCompletedIntubation; DifficultUnited States
-
International Institute of Rescue Research and...Completed
-
ResMedLymphatic Solutions, LLCCompletedLymphedema | Lymphedema, Secondary | Lymphedema, Lower Limb | Lymphedema of Leg | Lymphedema PrimaryUnited States
-
University of Alabama at BirminghamRecruitingParkinson DiseaseUnited States